ERBB2 and breast cancer: For example, in a recent study, melittin derivates and melittin were found to induce apoptosis of the aggressive triple-negative and HER2-enriched breast cancer subtypes by suppressing the activation of EGFR and HER2 receptors by blocking the phosphorylation in the plasma membrane of breast carcinoma cells [16].